Lenalidomide monotherapy or combination therapy can improve the efficacy of treatment to R/R ABC or non-GCB DLBCL (46), newly diagnosed high-risk DLBCL with MYC gene rearrangement (47), and DLBCL in immune-privileged sites (19–22). This evidence concerns the gene MYC and diffuse large B-cell lymphoma.